Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Waters (WAT)

Waters Q4 sales up 6% to $873 million; 2025 non-GAAP EPS guided to $12.70-$13.00

Positive Impact 3 of 5 earnings Written later

Waters reported fourth-quarter 2024 sales of $873 million, up 6% as reported and 8% in constant currency, and non-GAAP EPS of $4.10, up 13%. Full-year 2024 sales were flat at $2,958 million, while GAAP EPS fell to $10.71 from $10.84 and non-GAAP EPS rose 1% to $11.86. The company guided full-year 2025 non-GAAP EPS to $12.70 to $13.00 and reported sales growth of 2.5% to 5.0%, which gives shareholders a range for next year's earnings.

Key points

  • Q4 2024 sales were $873 million, above the high end of the company's guidance range, with Pharma sales up 10% in constant currency.
  • Q4 2024 GAAP diluted EPS was $3.88 versus $3.65 a year earlier; non-GAAP EPS was $4.10 versus $3.62.
  • Full-year 2024 sales were $2,958 million, flat versus $2,956 million in 2023; GAAP EPS was $10.71 versus $10.84.
  • 2025 guidance: non-GAAP EPS of $12.70 to $13.00 and reported sales growth of 2.5% to 5.0%, including an expected foreign exchange headwind of about 4% to EPS.

The filing

CompanyWaters (WAT)
Form8-K, current report
Filed with the SECFeb 12, 2025, 6:03 AM ET
Accession number0001193125-25-024730

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 12, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.